The vitamin C: Vitamin K3 system - Enhancers and inhibitors of the anticancer effect

Alternative Medicine Review

Volumn 15, Issue 4, 2010, Pages 345-351

  Lamson, Davis W ^a,b,c   Gu, Yu Huan ^a   Plaza, Steven M ^a,c,d   Brignall, Matthew S ^a,e   Brinton, Cathy A ^a,f   Sadlon, Angela E ^f  

^a BASTYR UNIVERSITY   (United States)

^b Tahoma Clinic   (United States)

^c Thorne Research   (United States)

^d Northwest Center for Natural Medicine   (United States)

^e SaluGenecists Inc   (United States)

^f NONE

Author keywords

Anticancer; Antioxidants; Ascorbate; Ascorbic acid; K 3; LNCaP; PC 3; Prostate cancer; Vitamin C; Vitamin K

Indexed keywords

ASCORBIC ACID; COLECALCIFEROL; CURCUMIN; HYDROGEN PEROXIDE; MELATONIN; MENADIONE; QUERCETIN; SUPEROXIDE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CYTOTOXIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; CELL CYCLE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; OXIDATIVE STRESS; PROSTATE TUMOR; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; CELL CYCLE; CHOLECALCIFEROL; CURCUMIN; CYTOTOXINS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MELATONIN; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; QUERCETIN; TUMOR CELLS, CULTURED; VITAMIN K 3;

EID: 79952291208     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 2005;102:13604-13609. (Pubitemid 41420895)
2. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979;59:527-605. (Pubitemid 9236599)
3. 2 gradients across biomembranes. FEBS Lett 2000;475:121-126.
4. 3 combinations against prostate cancer. In: Lucas JN, ed. Trends in Prostate Cancer Research. Hauppauge, NY: Nova Science Publishers, Inc.; 2005:189-236.
5. Sun Y, Oberley LW, Elwell JH, Sierra-Rivera E. Antioxidant enzyme activities in normal and transformed mouse liver cells. Int J Cancer 1989;44:1028-1033. (Pubitemid 20017838)
6. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol 1997;12:525-535. (Pubitemid 27240324)
7. Bostwick DG, Alexander EE, Singh R, et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000;89:123-134. (Pubitemid 30451282)
8. Verrax J, Stockis J, Tison A, et al. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol 2006;72:671-680. (Pubitemid 44233542)
9. Jamison JM, Gilloteaux J, Nassiri MR, et al. Cell cycle arrest and autoschizis in a human bladder carcinoma cell line following vitamin C and vitamin K3 treatment. Biochem Pharmacol 2004;67:337-351. (Pubitemid 38112764)
10. Gilloteaux J, Jamison JM, Neal DR, Summers JL. Cell death by autoschizis in TRAMP prostate carcinoma cells as a result of treatment by ascorbate: menadione combination. Ultrastruct Pathol 2005;29:221-235. (Pubitemid 40993748)
11. Beck R, Verrax J, Dejeans N, et al. Menadione reduction by pharmacological doses of ascorbate induces an oxidative stress that kills breast cancer cells. Int J Toxicol 2009;28:33-42.
12. Gilloteaux J, Jamison JM, Lorimer HE, et al. Autoschizis: a new form of cell death for human ovarian carcinoma cells following ascorbate:menadione treatment. Nuclear and DNA degradation. Tissue Cell 2004;36:197-209.
13. Gilloteaux J, Jamison JM, Neal DR, et al. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol 2010;34:140-160.
14. Verrax J, Cadrobbi J, Marques C, et al. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis 2004;9:223-233. (Pubitemid 38987599)
15. Verrax J, Delvaux M, Beghein N, et al. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res 2005;39:649-657. (Pubitemid 40846837)
16. Tareen B, Summers JL, Jamison JM, et al. A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. Int J Med Sci 2008;5:62-67. (Pubitemid 351871013)
17. Lasalvia-Prisco E, Cucchi S, Vazquez J, et al. Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer. Med Oncol 2003;20:45-52. (Pubitemid 36344025)
18. Gu YH, Sivam G. Cytotoxic effect of oyster mushroom Pleurotus ostreatus on human androgen-independent prostate cancer PC-3 cells. J Med Food 2006;9:196-204. (Pubitemid 44036109)
19. Hoang BX, Shaw DG, Pham PT, Levine SA. Neurobiological effects of melatonin as related to cancer. Eur J Cancer Prev 2007;16:511-516. (Pubitemid 350307500)
20. Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res 2006;66:9789-9793. (Pubitemid 44672026)
21. Vijayalaxmi, Thomas CR Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20:2575-2601.
22. Von Low EC, Perabo FG, Siener R, Muller SC. Review. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo 2007;21:189-204. (Pubitemid 46534271)
23. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010;17:190-197.
24. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: Quercetin. Altern Med Rev 2000;5:196-208.
25. Hirpara KV, Aggarwal P, Mukherjee AJ, et al. Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med Chem 2009;9:138-161.
26. Lou YR, Qiao S, Talonpoika R, et al. The role of vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 2004;92:317-325. (Pubitemid 40128252)
27. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 2003;88:363-371. (Pubitemid 36119910)
28. Gulcin I, Buyukokuroglu ME, Oktay M, Kufrevioglu OI. On the in vitro antioxidative properties of melatonin. J Pineal Res 2002;33:167-171.
29. Sliwinski T, Rozej W, Morawiec-Bajda A, et al. Protective action of melatonin against oxidative DNA damage: chemical inactivation versus base-excision repair. Mutat Res 2007;634:220-227. (Pubitemid 47634011)
30. Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 1985;19:517-521. (Pubitemid 16254595)
31. 3. Cancer Epidemiol Biomarkers Prev 1998;7:391-395.
32. Flanagan JN, Young MV, Persons KS, et al. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res 2006;26:2567-2572. (Pubitemid 44155536)
33. 2 as therapeutic agents for prostate cancer. Clin Cancer Res 2000;6:901-908.
34. Hsu JY, Feldman D, McNeal JE, Peehl DM. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25 hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001;61:2852-2856. (Pubitemid 32691924)
35. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
36. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009;75:1392-1399.
37. 3 is an active hormone in human primary prostatic stromal cells. FASEB J 2004;18:332-334.
38. Lou YR, Molnar F, Perakyla M, et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol 2010;118:162-170.
39. Falsone SF, Kurkela R, Chiarandini G, et al. Ligand affinity, homodimerization, and ligand induced secondary structural change of the human vitamin D receptor. Biochem Biophys Res Commun 2001;285:1180-1185. (Pubitemid 32912905)
40. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 1999;4:304-329. (Pubitemid 29526338)
41. Lamson DW, Brignall MS. Antioxidants and cancer therapy U: quick reference guide. Altern MedRev 2000;5:152-163. (Pubitemid 30226471)